HOPE-2 trial
Jump to navigation
Jump to search
Introduction
Study characteristics:
- international randomized trial
- 5522 patients with history of cardiovascular disease or diabetes plus cardiovascular risk factor
Treatment:
- combined B vitamins daily
- folic acid 2.5 mg
- vitamin B6 50 mg
- vitamin B12 1 mg
- placebo
Follow-up of 5 years
Primary endpoint: myocardial infarction, stroke, or cardiovascular death
Results:
- mean homocysteine levels 25% lower in B vitamin group than in placebo group
- no significant difference in primary endpoint (18.8% vs. 19.8%; P=0.41)
- no significant difference in secondary outcomes
- no benefit for patients with highest baseline homocysteine
- no benefit for patients from countries without mandatory folate fortification of food
More general terms
Additional terms
References
- ↑ Lonn E, Held C, Arnold JM, Probstfield J, McQueen M, Micks M, Pogue J, Sheridan P, Bosch J, Genest J, Yusuf S; HOPE-2 Investigators. Rationale, design and baseline characteristics of a large, simple, randomized trial of combined folic acid and vitamins B6 and B12 in high-risk patients: the Heart Outcomes Prevention Evaluation (HOPE)-2 trial. Can J Cardiol. 2006 Jan;22(1):47-53. PMID: https://www.ncbi.nlm.nih.gov/pubmed/16450017
Bonaa KH, Njolstad I, Ueland PM, Schirmer H, Tverdal A, Steigen T, Wang H, Nordrehaug JE, Arnesen E, Rasmussen K. Homocysteine Lowering and Cardiovascular Events after Acute Myocardial Infarction. N Engl J Med. 2006 Mar 12; [Epub ahead of print] PMID: https://www.ncbi.nlm.nih.gov/pubmed/16531614
Loscalzo J. Homocysteine Trials -- Clear Outcomes for Complex Reasons. N Engl J Med. 2006 Mar 14; [Epub ahead of print] PMID: https://www.ncbi.nlm.nih.gov/pubmed/16531615